{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T20:33:27Z","timestamp":1794861207112,"version":"4.9.1"},"reference-count":42,"publisher":"American Society of Hematology","issue":"5","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,3,10]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Bruton tyrosine kinase inhibitors (BTKis) have dramatically changed the therapeutic landscape of chronic lymphocytic leukemia (CLL), with ibrutinib, first-in-class, demonstrating durable efficacy even in high-risk patients. However, off-target adverse events (AEs) have raised concerns, prompting the development of more selective second-generation BTKis, such as zanubrutinib, designed to improve tolerability while maintaining efficacy. Despite encouraging results from clinical trials, real-world data comparing zanubrutinib with ibrutinib remain limited. In this multicenter, retrospective study, we analyzed 934 patients with CLL treated outside clinical trials, including 393 receiving zanubrutinib and 541 receiving ibrutinib. We evaluated time to treatment discontinuation (TTD) and time to next treatment or death (TTNTD) in both the overall cohort and a propensity score\u2013matched population. Patients who were treated with zanubrutinib experienced lower 12-month discontinuation rates (overall: 12.6% vs 21.4%; matched: 12.4% vs 20.2%) and higher 12-month TTNTD rates (overall: 91.9% vs 83.0%; matched: 93.2% vs 83.4%). Multivariable analyses confirmed zanubrutinib as an independent predictor of longer TTD and TTNTD, whereas high-risk features, including age, relapsed\/refractory disease, Binet stage C, TP53 disruption, Eastern Cooperative Oncology Group 2 to 3, and congestive heart failure, were consistently associated with poorer outcomes. AEs leading to discontinuation, particularly atrial fibrillation, bleeding, and infections, were less frequent with zanubrutinib, reflecting its favorable safety profile. These findings provide real-world evidence that zanubrutinib offers more durable disease control and improved persistence compared with ibrutinib, reinforcing its clinical value as a preferred second-generation BTKi. Nevertheless, the relatively short follow-up for zanubrutinib warrants cautious interpretation of long-term outcomes, and underscores the need for ongoing observation to fully characterize its durability and safety.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025018757","type":"journal-article","created":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T22:00:51Z","timestamp":1767823251000},"page":"1687-1699","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":6,"title":["Real-world safety and effectiveness of zanubrutinib vs ibrutinib in CLL: the CLL-ZANU2024 Italian cohort"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8504-3231","authenticated-orcid":false,"given":"Enrica Antonia","family":"Martino","sequence":"first","affiliation":[{"name":"1Hematology Unit, Department of Onco-hematology, Azienda Ospedaliera Annunziata, Cosenza, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7768-3925","authenticated-orcid":false,"given":"Annalisa","family":"Pitino","sequence":"additional","affiliation":[{"name":"2Institute of Clinical Physiology, National Research Council, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernesto","family":"Vigna","sequence":"additional","affiliation":[{"name":"1Hematology Unit, Department of Onco-hematology, Azienda Ospedaliera Annunziata, Cosenza, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2253-8883","authenticated-orcid":false,"given":"Raffaella","family":"Pasquale","sequence":"additional","affiliation":[{"name":"3Azienda Sanitaria Universitaria Friuli Centrale, SOC Clinica Ematologia, Udine, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9867-8335","authenticated-orcid":false,"given":"Isacco","family":"Ferrarini","sequence":"additional","affiliation":[{"name":"4Department of Engineering for Innovation Medicine, University of Verona, Verona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Moia","sequence":"additional","affiliation":[{"name":"5Division of Hematology, Department of Translational Medicine, Universit\u00e0 del Piemonte Orientale, Novara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0271-7200","authenticated-orcid":false,"given":"Andrea","family":"Visentin","sequence":"additional","affiliation":[{"name":"6Hematology Unit, Department of Medicine, University of Padova, Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Sanna","sequence":"additional","affiliation":[{"name":"7Hematology Unit, Department of Oncology, Azienda Ospedaliero Universitaria Careggi, Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Motta","sequence":"additional","affiliation":[{"name":"8Department of Hematology, Azienda Socio-Sanitaria Territoriale Spedali Civili di Brescia, Lombardy, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Moratti","sequence":"additional","affiliation":[{"name":"3Azienda Sanitaria Universitaria Friuli Centrale, SOC Clinica Ematologia, Udine, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Sportoletti","sequence":"additional","affiliation":[{"name":"9Centro di Ricerca Emato-Oncologica, Dipartimento di Medicina e Chirurgia Universit\u00e0 di Perugia, Perugia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalisa","family":"Chiarenza","sequence":"additional","affiliation":[{"name":"10Division of Hematology, Azienda Policlinico-S. Marco, University of Catania, Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Maggi","sequence":"additional","affiliation":[{"name":"11Haematology, Ospedale G. Moscati, Taranto, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Zammit","sequence":"additional","affiliation":[{"name":"12Oncoematology and Trapianto di Midollo Osseo Unit, Oncology Department Ospedale La Maddalena Palermo, Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Merli","sequence":"additional","affiliation":[{"name":"13Hematology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Ca' Granda, Ospedale Maggiore Policlinico, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Idanna","family":"Innocenti","sequence":"additional","affiliation":[{"name":"14Dipartimento di Scienze di Laboratorio ed Ematologiche, Area Ematologia, Fondazione Policlinico Universitario A. Gemelli Istituto di Ricovero e Cura a Carattere Scientifico, Universit\u00e0 Cattolica del Sacro Cuore, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Giordano","sequence":"additional","affiliation":[{"name":"15Department of Clinical Medicine and Surgery, Federico II University Medical School, Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Nocilli","sequence":"additional","affiliation":[{"name":"16Department of Hematology, Azienda Ospedaliera Papardo, Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimiliano","family":"Postorino","sequence":"additional","affiliation":[{"name":"17Hematology Department of Biomedicine and Prevention, Tor Vergata University of Rome, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Stelitano","sequence":"additional","affiliation":[{"name":"18Department of Hematology, Azienda Ospedaliera Bianchi Melacrino Morelli, Reggio Calabria, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Ferrario","sequence":"additional","affiliation":[{"name":"19Department of Medicine and Surgery, University of Insubria and Department of Oncology, Azienda Socio-Sanitaria Territoriale Sette Laghi, Ospedale di Circolo, Varese, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2587-7901","authenticated-orcid":false,"given":"Anna Maria","family":"Frustaci","sequence":"additional","affiliation":[{"name":"20Department of Haematology, Niguarda Cancer Center, Azienda Socio-Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcello","family":"Riva","sequence":"additional","affiliation":[{"name":"21Hematology Department, Ospedale San Bortolo di Vicenza, Vicenza, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Pepe","sequence":"additional","affiliation":[{"name":"22Hematology, Department of Translational and Precision Medicine, Sapienza University, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-7363-8684","authenticated-orcid":false,"given":"Adalberto","family":"Ibatici","sequence":"additional","affiliation":[{"name":"23Hematology and Cellular Therapy Unit, Istituto di Ricovero e Cura a Carattere Scientifico Ospedale Policlinico San Martino, Genoa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Scardino","sequence":"additional","affiliation":[{"name":"24Hematology and Stem Cell Transplant Unit, \u201cVito Fazzi\u201d Hospital, Lecce, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Anticoli Borza","sequence":"additional","affiliation":[{"name":"25Unit\u00e0 Operativa Complessa Ematologia, Azienda Ospedaliera San Giovanni-Addolorata, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Ballotta","sequence":"additional","affiliation":[{"name":"26Dipartimento Clinico di Scienze Mediche, Chirurgiche e della Salute, Universit\u00e0 degli Studi di Trieste, Trieste, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatrice","family":"Mancuso","sequence":"additional","affiliation":[{"name":"27Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, Hematology Unit, University of Palermo, Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3041-9606","authenticated-orcid":false,"given":"Francesco","family":"Malaspina","sequence":"additional","affiliation":[{"name":"28Hematology Unit, Istituto di Ricovero e Cura a Carattere Scientifico, IRST Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori \u201cDino Amadori,\u201d Meldola, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Mele","sequence":"additional","affiliation":[{"name":"29Haematology, Ospedale Cardinale Panico, Lecce, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7899-5966","authenticated-orcid":false,"given":"Sara","family":"Galimberti","sequence":"additional","affiliation":[{"name":"30Division of Hematology, University Hospital of Pisa, Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1743-9525","authenticated-orcid":false,"given":"Gioacchino","family":"Catania","sequence":"additional","affiliation":[{"name":"31Struttura Complessa a Direzione Universitaria Ematologia-Azienda Ospedaliero-Universitaria di Sassari Antonio e Biagio e C. Arrigo, Alessandria, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annamaria","family":"Giordano","sequence":"additional","affiliation":[{"name":"32Unit of Hematology and Stem Cell Transplantation, Azienda Ospedaliero-Universitaria Careggi Policlinico, Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Angeletti","sequence":"additional","affiliation":[{"name":"33Department of Medicine and Surgery, University of Perugia and Hematology\/Oncology Unit, Terni Hospital, Terni, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luana","family":"Schiattone","sequence":"additional","affiliation":[{"name":"34Dipartimento di Ematologia Clinica Ospedale civile S. Spirito Pescara, Pescara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-8041-6424","authenticated-orcid":false,"given":"Elsa","family":"Pennese","sequence":"additional","affiliation":[{"name":"34Dipartimento di Ematologia Clinica Ospedale civile S. Spirito Pescara, Pescara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosanna","family":"Miccolis","sequence":"additional","affiliation":[{"name":"35Department of Hematology, Azienda Sanitaria Locale\u2013Barletta Andria TraniI, Barletta, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1214-0193","authenticated-orcid":false,"given":"Angelo","family":"Fama","sequence":"additional","affiliation":[{"name":"36Hematology Unit, Department of Internal Medicine, Ospedale G. Mazzini, Teramo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6932-5028","authenticated-orcid":false,"given":"Giulio","family":"Giordano","sequence":"additional","affiliation":[{"name":"37Unit\u00e0 Operativa Complessa, Medicina Servizio e Ambulatorio di Ematologia Ospedale di Riferimento Regionale Antonio Cardarelli, Campobasso, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catello","family":"Califano","sequence":"additional","affiliation":[{"name":"38Onco-Hematology Unit, \u201cA. Tortora\u201d Hospital, Pagani, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Bruzzese","sequence":"additional","affiliation":[{"name":"1Hematology Unit, Department of Onco-hematology, Azienda Ospedaliera Annunziata, Cosenza, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0698-1781","authenticated-orcid":false,"given":"Santino","family":"Caserta","sequence":"additional","affiliation":[{"name":"1Hematology Unit, Department of Onco-hematology, Azienda Ospedaliera Annunziata, Cosenza, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuliana","family":"Farina","sequence":"additional","affiliation":[{"name":"39Hematology, Hospital \u201cSant\u2019Anna e San Sebastiano,\u201d Caserta, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Bulian","sequence":"additional","affiliation":[{"name":"40Clinical and Experimental Onco-Hematology Unit, Centro di Riferimento Oncologico di Aviano, Istituto di Ricovero e Cura a Carattere Scientifico, Aviano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo","family":"Loseto","sequence":"additional","affiliation":[{"name":"41Hematology and Cell Therapy Unit, Istituto di Ricovero e Cura a Carattere Scientifico Istituto Tumori \u201cGiovanni Paolo II,\u201d Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Pocali","sequence":"additional","affiliation":[{"name":"42Division of Hematology and Stem Cell Transplantation Unit, Cardarelli Hospital, Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Innao","sequence":"additional","affiliation":[{"name":"43Hematology Unit, Azienda Ospedaliera di Rilievo Nazionale e di Alta Specializzazione Garibaldi, Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piero","family":"Galieni","sequence":"additional","affiliation":[{"name":"44Department of Haematology and Stem Cell Transplantation Unit, C. e G. Mazzoni Hospital, Ascoli Piceno, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Fraticelli","sequence":"additional","affiliation":[{"name":"45Department of Hematology, Gemelli Molise, Campobasso, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2592-8724","authenticated-orcid":false,"given":"Candida","family":"Vitale","sequence":"additional","affiliation":[{"name":"46Division of Hematology, Azienda Ospedaliero Universitaria Citt\u00e0 della Salute e della Scienza di Torino, Turin, Italy"},{"name":"47Department of Molecular Biotechnology and Health Sciences, University of Turin, Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azzurra","family":"Romeo","sequence":"additional","affiliation":[{"name":"48Hematology Unit, Ospedale Santa Maria Goretti, Latina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7258-475X","authenticated-orcid":false,"given":"Marco","family":"Rossi","sequence":"additional","affiliation":[{"name":"49Department of Hematology-Oncology, Azienda Universitaria Ospedaliera Renato Dulbecco, Catanzaro, Italy"},{"name":"50Department of Experimental and Clinical Medicine Magna Grecia University, Catanzaro, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Scortechini","sequence":"additional","affiliation":[{"name":"51Azienda Ospedaliero Universitaria delle Marche, Ancona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Vozella","sequence":"additional","affiliation":[{"name":"52Hematology, Stem Cell Transplantation, Fondazione Policlinico Universitario Campus Bio medico di Roma, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Malandruccolo","sequence":"additional","affiliation":[{"name":"53Hematology Unit Ospedale \u201cFabrizio Spaziani,\u201d Frosinone, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marzia","family":"Varettoni","sequence":"additional","affiliation":[{"name":"54Division of Hematology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo di Pavia, Pavia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Morello","sequence":"additional","affiliation":[{"name":"55Unit\u00e0 Operativa di Ematologia, Ospedale Guglielmo da Saliceto, Piacenza, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1717-8337","authenticated-orcid":false,"given":"Giuseppe","family":"Pietrantuono","sequence":"additional","affiliation":[{"name":"56Istituto di Ricovero e Cura a Carattere Scientifico Oncology Referral Cancer Center of Basilicata, Rionero in Vulture, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4957-2045","authenticated-orcid":false,"given":"Esmeralda","family":"Conte","sequence":"additional","affiliation":[{"name":"57Haematology Unit, Department of Clinical and Molecular Medicine, Sant'Andrea University Hospital, Sapienza University, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Cantelli","sequence":"additional","affiliation":[{"name":"58Unit\u00e0 di Ematologia, Ospedale Santa Maria delle Croci, Ravenna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9792-9542","authenticated-orcid":false,"given":"Roberta","family":"Murru","sequence":"additional","affiliation":[{"name":"59Hematology and Stem Cell Transplantation Unit, Ospedale Oncologico A. Businco, Azienda di Rilievo Nazionale e di Alta Specializzazione G. Brotzu, Cagliari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Caracciolo","sequence":"additional","affiliation":[{"name":"50Department of Experimental and Clinical Medicine Magna Grecia University, Catanzaro, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7154-8140","authenticated-orcid":false,"given":"Enrico","family":"Derenzini","sequence":"additional","affiliation":[{"name":"60Division of Onco-Hematology, European Institute of Oncology Istituto di Ricovero e Cura a Carattere Scientifico, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Di Martina","sequence":"additional","affiliation":[{"name":"61Hematology Unit, Ospedale San Vincenzo, Taormina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6431-6878","authenticated-orcid":false,"given":"Roberto","family":"Marasca","sequence":"additional","affiliation":[{"name":"62Hematology Unit, Department of Oncology and Hematology Azienda-Ospedaliero Universitaria of Modena, Policlinico Modena, Modena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3958-0669","authenticated-orcid":false,"given":"Maria Ilaria","family":"Del Principe","sequence":"additional","affiliation":[{"name":"17Hematology Department of Biomedicine and Prevention, Tor Vergata University of Rome, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3863-9884","authenticated-orcid":false,"given":"Amalia","family":"Figuera","sequence":"additional","affiliation":[{"name":"10Division of Hematology, Azienda Policlinico-S. Marco, University of Catania, Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7835-2573","authenticated-orcid":false,"given":"Francesco","family":"Angotzi","sequence":"additional","affiliation":[{"name":"6Hematology Unit, Department of Medicine, University of Padova, Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2123-7675","authenticated-orcid":false,"given":"Marta","family":"Coscia","sequence":"additional","affiliation":[{"name":"19Department of Medicine and Surgery, University of Insubria and Department of Oncology, Azienda Socio-Sanitaria Territoriale Sette Laghi, Ospedale di Circolo, Varese, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Di Renzo","sequence":"additional","affiliation":[{"name":"24Hematology and Stem Cell Transplant Unit, \u201cVito Fazzi\u201d Hospital, Lecce, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8327-1396","authenticated-orcid":false,"given":"Luca","family":"Laurenti","sequence":"additional","affiliation":[{"name":"14Dipartimento di Scienze di Laboratorio ed Ematologiche, Area Ematologia, Fondazione Policlinico Universitario A. Gemelli Istituto di Ricovero e Cura a Carattere Scientifico, Universit\u00e0 Cattolica del Sacro Cuore, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Amodio","sequence":"additional","affiliation":[{"name":"50Department of Experimental and Clinical Medicine Magna Grecia University, Catanzaro, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3277-6594","authenticated-orcid":false,"given":"Pellegrino","family":"Musto","sequence":"additional","affiliation":[{"name":"32Unit of Hematology and Stem Cell Transplantation, Azienda Ospedaliero-Universitaria Careggi Policlinico, Bari, Italy"},{"name":"63Department of Precision and Regenerative Medicine and Ionian Area, \u201cAldo Moro\u201d University School of Medicine, Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Di Raimondo","sequence":"additional","affiliation":[{"name":"10Division of Hematology, Azienda Policlinico-S. Marco, University of Catania, Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arcangelo","family":"Liso","sequence":"additional","affiliation":[{"name":"33Department of Medicine and Surgery, University of Perugia and Hematology\/Oncology Unit, Terni Hospital, Terni, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Tedeschi","sequence":"additional","affiliation":[{"name":"20Department of Haematology, Niguarda Cancer Center, Azienda Socio-Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1222-6149","authenticated-orcid":false,"given":"Livio","family":"Trentin","sequence":"additional","affiliation":[{"name":"6Hematology Unit, Department of Medicine, University of Padova, Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4681-0151","authenticated-orcid":false,"given":"Gianluca","family":"Gaidano","sequence":"additional","affiliation":[{"name":"5Division of Hematology, Department of Translational Medicine, Universit\u00e0 del Piemonte Orientale, Novara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca Romana","family":"Mauro","sequence":"additional","affiliation":[{"name":"22Hematology, Department of Translational and Precision Medicine, Sapienza University, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3580-4602","authenticated-orcid":false,"given":"Giovanni","family":"Tripepi","sequence":"additional","affiliation":[{"name":"64Clinical Epidemiology and Physiopathology of Renal Diseases and Hypertension of Reggio Calabria, Institute of Clinical Physiology, National Research Council, Reggio Calabria, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2585-7073","authenticated-orcid":false,"given":"Fortunato","family":"Morabito","sequence":"additional","affiliation":[{"name":"65AIL sezione di Cosenza, Cosenza, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valter","family":"Gattei","sequence":"additional","affiliation":[{"name":"40Clinical and Experimental Onco-Hematology Unit, Centro di Riferimento Oncologico di Aviano, Istituto di Ricovero e Cura a Carattere Scientifico, Aviano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5256-0726","authenticated-orcid":false,"given":"Massimo","family":"Gentile","sequence":"additional","affiliation":[{"name":"1Hematology Unit, Department of Onco-hematology, Azienda Ospedaliera Annunziata, Cosenza, Italy"},{"name":"66Department of Pharmacy, Health and Nutritional Science, University of Calabria, Rende, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,2,27]]},"reference":[{"issue":"1","key":"2026030916264243800_bib1","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.annonc.2020.09.019","article-title":"Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Eichhorst","year":"2021","journal-title":"Ann Oncol"},{"issue":"1","key":"2026030916264243800_bib2","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1215637","article-title":"Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia","volume":"369","author":"Byrd","year":"2013","journal-title":"N Engl J Med"},{"issue":"3","key":"2026030916264243800_bib3","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1400376","article-title":"Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia","volume":"371","author":"Byrd","year":"2014","journal-title":"N Engl J Med"},{"issue":"25","key":"2026030916264243800_bib4","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","article-title":"Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia","volume":"373","author":"Burger","year":"2015","journal-title":"N Engl J Med"},{"issue":"5","key":"2026030916264243800_bib5","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1056\/NEJMoa1817073","article-title":"Ibrutinib-rituximab or chemoimmunotherapy for chronic lymphocytic leukemia","volume":"381","author":"Shanafelt","year":"2019","journal-title":"N Engl J Med"},{"issue":"26","key":"2026030916264243800_bib6","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1812836","article-title":"Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL","volume":"379","author":"Woyach","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"2026030916264243800_bib7","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1470-2045(18)30788-5","article-title":"Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of CLL (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial","volume":"20","author":"Moreno","year":"2019","journal-title":"Lancet Oncol"},{"issue":"12","key":"2026030916264243800_bib8","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1002\/ajh.25638","article-title":"Final analysis from RESONATE: up to six years of follow-up on ibrutinib in previously treated CLL or SLL","volume":"94","author":"Munir","year":"2019","journal-title":"Am J Hematol"},{"issue":"11","key":"2026030916264243800_bib9","doi-asserted-by":"crossref","first-page":"3440","DOI":"10.1182\/bloodadvances.2021006434","article-title":"Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with CLL","volume":"6","author":"Barr","year":"2022","journal-title":"Blood Adv"},{"issue":"17","key":"2026030916264243800_bib10","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1182\/blood-2017-10-810044","article-title":"Single-agent ibrutinib in treatment-naive and relapsed\/refractory CLL: a 5-year experience","volume":"131","author":"O\u2019Brien","year":"2018","journal-title":"Blood"},{"issue":"8","key":"2026030916264243800_bib11","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.3324\/haematol.2014.104661","article-title":"Outcomes of first-line treatment for CLL with 17p deletion","volume":"99","author":"Strati","year":"2014","journal-title":"Haematologica"},{"issue":"9","key":"2026030916264243800_bib12","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1182\/bloodadvances.2023012221","article-title":"BTK inhibitors in CLL: second-generation drugs and beyond","volume":"8","author":"Tam","year":"2024","journal-title":"Blood Adv"},{"key":"2026030916264243800_bib13","unstructured":"European Medicines Agency\n          . Brukinsa (zanubrutinib) EPAR. Accessed 25 March 2025. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/brukinsa."},{"key":"2026030916264243800_bib14","unstructured":"Agenzia Italiana del Farmaco\n          . Determina 640-2023 Brukinsa. Accessed 25 March 2025. https:\/\/www.aifa.gov.it\/documents\/20142\/961234\/Determina_640-2023_Brukinsa.pdf."},{"issue":"7","key":"2026030916264243800_bib15","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1200\/JCO-24-02265","article-title":"Zanubrutinib versus bendamustine and rituximab in treatment-na\u00efve CLL\/SLL: median 5-year follow-up of SEQUOIA","volume":"43","author":"Shadman","year":"2025","journal-title":"J Clin Oncol"},{"issue":"26","key":"2026030916264243800_bib16","doi-asserted-by":"crossref","first-page":"2706","DOI":"10.1182\/blood.2024024667","article-title":"Sustained benefit of zanubrutinib vs ibrutinib in patients with R\/R CLL\/SLL: final comparative analysis of ALPINE","volume":"144","author":"Brown","year":"2024","journal-title":"Blood"},{"issue":"15","key":"2026030916264243800_bib17","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1182\/blood.2018884940","article-title":"Acalabrutinib monotherapy in patients with relapsed\/refractory chronic lymphocytic leukemia: updated phase 2 results","volume":"135","author":"Byrd","year":"2020","journal-title":"Blood"},{"issue":"5","key":"2026030916264243800_bib18","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1080\/14656566.2023.2194486","article-title":"Acalabrutinib in chronic lymphocytic leukemia","volume":"24","author":"Martino","year":"2023","journal-title":"Expert Opin Pharmacother"},{"issue":"16 suppl","key":"2026030916264243800_bib19","doi-asserted-by":"crossref","first-page":"e19020","DOI":"10.1200\/JCO.2024.42.16_suppl.e19020","article-title":"Real-world BTKi treatment patterns and outcomes among patients with CLL\/SLL in US community oncology practices","volume":"42","author":"Hou","year":"2024","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"2026030916264243800_bib20","doi-asserted-by":"crossref","first-page":"6554","DOI":"10.1182\/blood-2023-189110","article-title":"A real-world study of zanubrutinib treatment in CLL\/SLL","volume":"142","author":"Zhu","year":"2023","journal-title":"Blood"},{"issue":"suppl 1","key":"2026030916264243800_bib21","doi-asserted-by":"crossref","first-page":"6540","DOI":"10.1182\/blood-2023-180477","article-title":"Real-world outcomes of zanubrutinib monotherapy in CLL: a multicenter retrospective study","volume":"142","author":"Luo","year":"2023","journal-title":"Blood"},{"issue":"7","key":"2026030916264243800_bib22","doi-asserted-by":"crossref","first-page":"e128","DOI":"10.1002\/hem3.128","article-title":"CD49d expression is included in a revised 4-factor model predicting outcome in CLL patients treated with ibrutinib: a multicenter real-world experience","volume":"8","author":"Bomben","year":"2024","journal-title":"Hemasphere"},{"issue":"1","key":"2026030916264243800_bib23","doi-asserted-by":"crossref","first-page":"e3249","DOI":"10.1002\/hon.3249","article-title":"Ibrutinib as first-line therapy in CLL patients over 80 years old: a retrospective real-life multicenter Italian cohort","volume":"42","author":"Martino","year":"2024","journal-title":"Hematol Oncol"},{"issue":"4","key":"2026030916264243800_bib24","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1038\/s41375-023-01845-9","article-title":"Clinical impact of TP53 disruption in CLL patients treated with ibrutinib: a campus CLL study","volume":"37","author":"Bomben","year":"2023","journal-title":"Leukemia"},{"key":"2026030916264243800_bib25","doi-asserted-by":"crossref","first-page":"1033413","DOI":"10.3389\/fonc.2022.1033413","article-title":"Obinutuzumab plus chlorambucil versus ibrutinib in previously untreated CLL patients without TP53 disruptions: a real-life CLL campus study","volume":"12","author":"Visentin","year":"2022","journal-title":"Front Oncol"},{"issue":"2","key":"2026030916264243800_bib26","doi-asserted-by":"crossref","first-page":"E24","DOI":"10.1002\/ajh.26779","article-title":"Efficacy of front-line ibrutinib versus FCR in CLL: a retrospective multicenter real-world study","volume":"98","author":"Levi","year":"2023","journal-title":"Am J Hematol"},{"issue":"4","key":"2026030916264243800_bib27","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1182\/bloodadvances.2022007619","article-title":"Ibrutinib in patients over 80 with CLL: a multicenter Italian cohort","volume":"7","author":"Reda","year":"2023","journal-title":"Blood Adv"},{"issue":"3","key":"2026030916264243800_bib28","doi-asserted-by":"crossref","first-page":"E95","DOI":"10.1002\/ajh.26437","article-title":"Continuous treatment with ibrutinib in 100 untreated patients with TP53-disrupted CLL: a real-life campus CLL study","volume":"97","author":"Visentin","year":"2022","journal-title":"Am J Hematol"},{"issue":"8","key":"2026030916264243800_bib29","doi-asserted-by":"crossref","first-page":"E269","DOI":"10.1002\/ajh.26201","article-title":"Effectiveness of ibrutinib as first-line therapy for CLL patients and indirect comparison with rituximab-bendamustine outside clinical trials","volume":"96","author":"Morabito","year":"2021","journal-title":"Am J Hematol"},{"issue":"5","key":"2026030916264243800_bib30","doi-asserted-by":"crossref","first-page":"E168","DOI":"10.1002\/ajh.26127","article-title":"Assessment of the 4-factor score: retrospective analysis of 586 CLL patients receiving ibrutinib","volume":"96","author":"Morabito","year":"2021","journal-title":"Am J Hematol"},{"issue":"4","key":"2026030916264243800_bib31","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1111\/ejh.13573","article-title":"Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed\/resistant CLL cases","volume":"106","author":"Morabito","year":"2021","journal-title":"Eur J Haematol"},{"issue":"1","key":"2026030916264243800_bib32","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/s41375-020-0833-x","article-title":"Survival risk score for real-life relapsed\/refractory CLL patients receiving ibrutinib: a campus CLL study","volume":"35","author":"Gentile","year":"2021","journal-title":"Leukemia"},{"issue":"25","key":"2026030916264243800_bib33","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","article-title":"iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL","volume":"131","author":"Hallek","year":"2018","journal-title":"Blood"},{"issue":"5","key":"2026030916264243800_bib34","doi-asserted-by":"crossref","first-page":"874","DOI":"10.3324\/haematol.2017.182907","article-title":"Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis","volume":"103","author":"Mato","year":"2018","journal-title":"Haematologica"},{"issue":"1","key":"2026030916264243800_bib35","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s13045-020-00870-w","article-title":"Ibrutinib dose modifications in the management of CLL","volume":"13","author":"Hardy-Abeloos","year":"2020","journal-title":"J Hematol Oncol"},{"issue":"8","key":"2026030916264243800_bib36","doi-asserted-by":"crossref","first-page":"E166","DOI":"10.1002\/ajh.24773","article-title":"Real-world results of ibrutinib in relapsed\/refractory CLL in France: early results on a large series of 428 patients","volume":"92","author":"Ysebaert","year":"2017","journal-title":"Am J Hematol"},{"issue":"12","key":"2026030916264243800_bib37","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.3324\/haematol.2016.147900","article-title":"Ibrutinib for relapsed\/refractory CLL: a UK and Ireland analysis of outcomes in 315 patients","volume":"101","author":"UK CLL Forum","year":"2016","journal-title":"Haematologica"},{"issue":"8","key":"2026030916264243800_bib38","doi-asserted-by":"crossref","first-page":"E306","DOI":"10.1002\/ajh.26235","article-title":"TP53 disruption as a risk factor in the era of targeted therapies: a multicenter retrospective study of 525 CLL cases","volume":"96","author":"Morabito","year":"2021","journal-title":"Am J Hematol"},{"issue":"18","key":"2026030916264243800_bib39","doi-asserted-by":"crossref","first-page":"3612","DOI":"10.1158\/1078-0432.CCR-22-3217","article-title":"CD49d expression identifies a biologically distinct subtype of CLL with inferior progression-free survival on BTK inhibitor therapy","volume":"29","author":"Alsadhan","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"15","key":"2026030916264243800_bib40","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1182\/blood.2019003179","article-title":"CD49d promotes disease progression in CLL: new insights from CD49d bimodal expression","volume":"135","author":"Tissino","year":"2020","journal-title":"Blood"},{"issue":"2","key":"2026030916264243800_bib41","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1084\/jem.20171288","article-title":"Functional and clinical relevance of VLA-4 (CD49d\/CD29) in ibrutinib-treated CLL","volume":"215","author":"Tissino","year":"2018","journal-title":"J Exp Med"},{"issue":"16","key":"2026030916264243800_bib42","doi-asserted-by":"crossref","first-page":"4291","DOI":"10.1182\/bloodadvances.2023009739","article-title":"Real-world comparative effectiveness of acalabrutinib and ibrutinib in patients with CLL","volume":"7","author":"Roeker","year":"2023","journal-title":"Blood Adv"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/5\/1687\/2506415\/blooda_adv-2025-018757-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/5\/1687\/2506415\/blooda_adv-2025-018757-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T20:26:55Z","timestamp":1773088015000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/5\/1687\/565893\/Real-world-safety-and-effectiveness-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,27]]},"references-count":42,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,3,10]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025018757","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,3,10]]},"published":{"date-parts":[[2026,2,27]]}}}